18–20 June 2025 The 17th Annual World Cancer Congress (WCC) Stockholm, Sweden The 17th Annual World Cancer Congress (WCC-2025) will be held on June 18–20, 2025, in Stockholm, Sweden. We would like to extend a warm welcome to all distinguished guests from all over the world. The Annual World Cancer Congress (WCC), initiated in 2008, has been successfully organized in Dalian (China), Shanghai (China), Beijing (China), Nanjing (China), Xi’an (China), Philadelphia (USA), Tokyo (Japan), Lisbon (Portugal), Barcelona (Spain), Osaka (Japan), and Budapest (Hungary) and has attracted more than 5000 participants from over 50 countries and regions in the previous 16 years. The 17th annual meeting will offer the chance to meet and hear about the latest developments from the most prestigious researchers in the field. The scientific program will cover a wide variety of subjects in the field of basic cancer research, screening and diagnosis, cancer therapies, new drug trials, and epidemiology and prevention, providing a platform to all experts to discuss the latest research and achievements. https://www.bitcongress.com/cancer2025/registernow.asp

Innovative Medicines & Omics (IMO) is a peer-reviewed and open-access journal that publishes articles on the critical analysis of human health and animal medicine-related original omics research and its applications in innovative medicines.  The journal includes a variety of omics layers, such as genomics, proteomics, epigenomics metabolomics, lipidomics, peptidomics, metagenomics, microbiome, pharmacogenomics, toxicogenomics, etc., with the focus on disease etiology, prevention, treatment, prognosis and monitoring. Features include original research articles, reviews, case reports, short communications and editorials. Topics of particular interest include, but are not limited to: Disease evolution and heterogeneity Single-cell sequencing technique Circulating tumor cell Personalized medicine Drug sensitivity screening Combination therapy Drug resistance Disease therapeutic mechanism and marker detection Database and web server Computational method Assisted reproduction Embryonic development Animal organ regeneration Bioproduct and biomaterial Novel therapeutic strategies High-throughput screening Therapeutic targets Combinatorial chemistry, parallel synthesis and library design Drug delivery Advances in key compound classes and therapeutic areas Automation and technology Editor-in-Chief Prof. Enrico Mini Emeritus Professor of Medical Oncology,Department of Health Sciences, University of Florence, Florence, Italy   Prof. Changyuan YU College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China We welcome researchers and scholars in the related fields to submit manuscripts to IMO. IMO upholds high publishing standards and adheres to rigorous peer review prior to acceptance. Potential authors are encouraged to make submissions through online submission system： http://journals.accscience.com/index.php/IMO/login If you have any question about submissions and publications, please contact the Editorial Office at imo.office@accscience.sg.  Warm Regards,Editorial OfficeInnovative Medicines & Omics  AccScience Publishing

  We are pleased to announce that Prof. Enrico Mini joined Innovative Medicines & Omics as Editor-in-Chief. Name: Prof. Enrico Mini Email: enrico.mini@unifi.itAffiliation: Emeritus Professor of Medical Oncology, Department of Health Sciences, University of Florence, Florence, ItalyHomepage: https://www.researchgate.net/profile/Enrico-MiniResearch Interests: Gastrointestinal Cancers; Tumor Drug Resistance; Cancer Pharmacogenomics and Pharmacogenetics; Anticancer Drug Synergism Prof. Mini is an Emeritus Professor of Medical Oncology at the Department of Health Sciences, University of Florence (Italy). His research interests comprise the mechanisms of tumor drug resistance, in particular to antimetabolites and metal-based drugs, cancer pharmacogenomics and pharmacogenetics, and controlled clinical trials in gastrointestinal cancers. His studies have contributed to the advancement of knowledge in the field of biochemical bases of anticancer drug synergism and molecular bases of anticancer drug resistance. Prof. Mini is the author of more than 190 original articles in international peer-reviewed journals and about 80 reviews, editorials, book chapters, and letters. He has given over 260 invited talks at national and international conferences and seminars at Italian and foreign universities and has presented more than 350 communications at scientific congresses. In recognition of his outstanding achievements, Prof. Mini has received various awards and recognitions and grants for his research results, including the Leukemia Society of America Special Fellow Award in 1982, the Lady Tata Memorial Trust Award, the Alberico Benedicenti Italian Society of Pharmacology Special Mention Award in 1988 and in 2019 the 'International Society of Antimicrobial Chemotherapy (ISAC) Fellow Award (London). Prof. Mini has also held prestigious positions in various scientific societies. He is currently the Coordinator of the Cancer Pharmacology Working Group of the Italian Society of Pharmacology. We warmly welcome Prof. Enrico Mini in his new role as Editor-in-Chief, and we look forward to his leading Innovative Medicines & Omics to many more milestones.

Innovative Medicines & Omics [IMO] publishes rigorously peer-reviewed and high-quality original research articles and authoritative reviews that focus on pharmacy and omics in the field of animal and human health.  Now we are currently looking for Editorial Board Members for our journal. This is an opportunity to exchange with and learn from experts in the same field. As you may know, IMO is an international, double-blind peer-reviewed, quick-refereeing open-access journal. The journal was launched in April, 2023 by cooperating with Beijing University of Chemical Technology by Singapore AccScience Publishing (ASP, https://accscience.com/). We have already established a very good Editorial Board:https://accscience.com/journal/IMO/about/editorial_board  We encourage applications from researchers with a background in a range of subject areas (https://accscience.com/journal/IMO/about/aims_scope). If you are passionate about participating in cutting-edge research publications, please do not hesitate to contact us about joining the board and contributing to the journal. This position is open to experts in all aspects of medicine and omics research. To apply for this position, recommend potential candidates or request further information, please contact (imo.office@accscience.sg) from the Innovative Medicines & Omics Editorial Office.   Welcome to join us! Innovative Medicines & Omics Editorial Office

Innovative Medicines & Omics [IMO] publishes rigorously peer-reviewed and high-quality original research articles and authoritative reviews that focus on pharmacy and omics in the field of animal and human health.  Now we are currently looking for 1-2 Associate Editors for our journal. This is an opportunity to exchange with and learn from experts in the same field. IMO is an international, double-blind peer-reviewed, quick-refereeing open-access journal. The journal was launched in April, 2023 by cooperating with Beijing University of Chemical Technology by Singapore AccScience Publishing (ASP, https://accscience.com/).  We have already established a very good Editorial Board: https://accscience.com/journal/IMO/about/editorial_board We encourage applications from researchers with a background in a range of subject areas (https://accscience.com/journal/IMO/about/aims_scope).Should you decide to serve on this position, you would be responsible for some of the following tasks depending on your availability: - Assisting the Editor-in-Chief in journal management;- Inviting additional scientists to join the Editorial Board;- Recommending timely topics and suggesting potential guest editors;- Publishing one paper per year, free of charge, in open access;- Promoting the journal. As we provide a low-cost publishing service in open access format, we unfortunately cannot additionally pay an honorarium. The term of the Associate Editor membership is three years and could then be renewed. We believe that your expertise together with our rigorous editorial policies can build a high-standard journal specifically dedicated to Pharmacy and Omics research. If you are interested in becoming an Associate Editor for IMO, please send your full academic CV and a short cover letter that details your interest and enthusiasm for the position to imo.office@accscience.sg <imo.office@accscience.sg>. Welcome to join us! Innovative Medicines & Omics Editorial Office